Skip to content
Live news Screener Coverage Pricing Docs REST API WebSocket API MCP server Company Use cases Blog Changelog Status Compare Contact
BIVI$1.24-0.04(-3.13%)From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television[10:30:00 AM ET]AMGN$439.26-8.02(-1.79%)IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's...[10:30:00 AM ET]JNJ$263.81-3.80(-1.42%)Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of...[8:54:00 AM ET]PBLS$24.79-2.13(-7.91%)Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors[8:45:00 AM ET]SMTC$131.80+6.68(+5.34%)Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026[8:00:00 AM ET]GMAB$43.85+3.85(+9.63%)Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]INCY$115.00-1.93(-1.65%)Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]NBTX$29.36+0.17(+0.58%)NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma[7:00:00 AM ET]ONC$377.63-4.64(-1.21%)BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026[4:15:00 AM ET]CMPX$0.77-0.03(-3.97%)Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026[4:15:00 AM ET]CELC$63.20-2.37(-3.61%)Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026[4:15:00 AM ET]

ASTH · NASDAQ

Astrana Health, Inc.

$37.45 -0.60 (-1.58%)

Company overview

Astrana Health, Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company leverages its proprietary population health management and healthcare delivery platform to operate an integrated, value-based healthcare model that empowers providers in its network to deliver care to their patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Its physician network includes primary care physicians, specialist physicians and extenders, and hospitalists.

Sector
Healthcare
Industry
Medical - Care Facilities
Exchange
NASDAQ
Market cap
$1.9B
Employees
1,900
Headquarters
Alhambra, CA
CEO
Brandon K. Sim
Listed
March 11, 2009
P/E
60.64
Dividend yield
0.00%

Company financials

Revenue
$3.5B
Gross profit
$328M
Operating income
$86.5M
EBITDA
$149M
Net income
$30.2M
EPS
$0.62
Total assets
$2.4B
Total debt
$1.1B
Gross margin
9.31%
Net margin
0.86%
Earnings yield
1.65%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

29.6635.3541.0546.7552.44
ASTH 1D NASDAQ O37.67H37.88L37.15C37.41-0.60 (-1.58%)Vol34.08K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Source
Date
Type
Ticker Type Headline Source Published
ASTH Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Astrana Health, Inc. - ASTH ACCESS Newswire
ASTH Press release How Artificial Intelligence Is Reshaping Preventive Care Across the U.S. GlobeNewswire
ASTH Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Astrana Health, Inc.- ASTH GlobeNewswire
ASTH Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Astrana Health, Inc. - ASTH ACCESS Newswire
ASTH Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Astrana Health, Inc.- ASTH PRNewsWire
ASTH Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Astrana Health, Inc. - ASTH ACCESS Newswire
ASTH Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Astrana Health, Inc.- ASTH ACCESS Newswire
ASTH Stock news Astrana Health, Inc. Schedules 2026 Third Quarter Financial Results Release and Conference Call PRNewsWire
ASTH Stock news Astrana Health, Inc. (NASDAQ:ASTH) Stock Rated “Moderate Buy” by Wall Street Analysts Defense World
ASTH Legal ASTH Investors Have Opportunity to Join Astrana Health, Inc. Fraud Investigation with SBS Law Business Wire
ASTH Press release PRIVACY ALERT: AWKO Law Investigating Astrana Health Data Breach Business Wire
ASTH Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Astrana Health, Inc.- ASTH GlobeNewswire
ASTH Press release Lowey Dannenberg, P.C. is Investigating Astrana Health, Inc. (NASDAQ: ASTH) for Potential Violations of the Federal Securities Laws GlobeNewsWire
ASTH Stock news Astrana Health: 81% Full-Risk And Profitable Seeking Alpha
ASTH Stock news Astrana Health, Inc. (ASTH) Q2 2026 Earnings Call Transcript Seeking Alpha
ASTH Stock news Astrana Health, Inc. (ASTH) Q2 Earnings Top Estimates Zacks Investment Research
ASTH Stock news Astrana Health Q2 Earnings Call Highlights MarketBeat
ASTH Press release Astrana Health, Inc. Reports Second Quarter 2026 Results PRNewsWire
ASTH Press release Astrana Health, Inc. Schedules 2026 Second Quarter Financial Results Release and Conference Call PRNewsWire
ASTH Press release Astrana Health ACOs Deliver $120.4 Million in Gross Shared Savings in 2024 Performance Year PRNewsWire
FAQ

Questions about Astrana Health, Inc.

What does Astrana Health, Inc. do?
Astrana Health, Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company leverages its proprietary population health management and healthcare delivery platform to operate an integrated, value-based healthcare model that empowers providers in its network to deliver care to their patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Its physician network includes primary care physicians, specialist physicians and extenders, and hospitalists.
What is ASTH's market cap?
Astrana Health, Inc. (ASTH) is a listed stock with a live quote. The latest market cap on this page is $1.9B.
Where is Astrana Health, Inc. headquartered?
Astrana Health, Inc. is headquartered in Alhambra, CA.
How do I get ASTH news from the API?
Call GET /v1/news?tickers=ASTH. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does ASTH news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ASTH, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the ASTH price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 2,000 REST requests a day. Paid Pro removes the daily cap. If you don't subscribe, the account stays on Free.